Overview

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Phase:

Phase 3

Details

Lead Sponsor:

Addrenex Pharmaceuticals, Inc.

Treatments:

Clonidine